Tandem Diabetes Care has announced that its t:slim X2 insulin pump, featuring Control-IQ automated insulin delivery technology, received approval for use with the ultra-rapid-acting insulin, Lyumjev (insulin lispro-aabc injection) from Eli Lilly, in the European Union (EU).
This clearance follows the EU’s general authorisation of Lyumjev for insulin pump usage in 2020, which necessitates individual compatibility testing for each pump and AID system.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
To achieve this compatibility, Tandem and Eli Lilly conducted clinical trials to demonstrate the benefits of using Lyumjev with the Control-IQ technology.
The collaboration between the two companies extends beyond the EU, as they aim to secure Lyumjev compatibility for the t:slim X2 pump in additional regions and for the Tandem Mobi pump.
Tandem Diabetes Care chief medical officer Dr Jordan Pinsker said: “High satisfaction and quality of life benefits were recently shown in a clinical study using Lyumjev with Control-IQ technology.
“Ultra-rapid acting insulin is a popular choice for people living with diabetes due to its fast response time. We are proud to be able to offer Lyumjev compatibility with our t:slim X2 pump as part of an AID system in the EU, providing more flexibility for our customers in these countries.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe t:slim X2 pump is already approved for use with several U-100 insulins, including Humalog and Novolog/NovoRapid globally, as well as Admelog/Insulin lispro Sanofi and Trurapi/Insulin aspart Sanofi in Canada and selected countries in the EU.
In February 2024, Tandem Diabetes Care announced the commercial launch of its Tandem Mobi insulin delivery system in the US.
